Literature DB >> 9261581

Prognostic indices in peritonitis.

C Ohmann1, T Hau.   

Abstract

In this review an update concerning the prognostic factors and scoring systems in peritonitis is given. The course of the disease is influenced by the physiological reserve of the patient, the acute severity and the type of the disease, the success of the operation and subsequent management and complications. The Acute Physiology and Chronic Health Evaluation Score (APACHE II) may be used with pre-operative data for the assessment of the severity of the disease or with postoperative data for monitoring. The Mannheim Peritonitis Index (MPI) and the Peritonitis Index Altona are based on pre- and intraoperative data and are also used for severity assessment. Treatment selection with respect to re-operation is supported by the Prognostic Peritonitis Model and the Abdominal Re-operation Predictive Index, covering data from the pre-, intra- and postoperative period. Adequate evaluation data are available for APACHE II and MPI, showing that these instruments are useful for risk assessment, definition of inclusion/exclusion criteria and analysis of comparability in clinical trials. Evaluation of treatment policies and quality assurance can best be performed with APACHE II, monitoring with APACHE II and Multiple Organ Failure scores. Support of individual patient care is still experimental.

Entities:  

Mesh:

Year:  1997        PMID: 9261581

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  14 in total

1.  Is severity of disease more important than choice of surgical treatment in secondary peritonitis?

Authors:  Bas Lamme; Marja A Boermeester
Journal:  Croat Med J       Date:  2006-02       Impact factor: 1.351

2.  Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis.

Authors:  Emilia Cercenado; Luis Torroba; Rafael Cantón; Luis Martínez-Martínez; Fernando Chaves; Jose Angel García-Rodríguez; Carmen Lopez-Garcia; Lorenzo Aguilar; César García-Rey; Nuria García-Escribano; Emilio Bouza
Journal:  J Clin Microbiol       Date:  2009-11-25       Impact factor: 5.948

3.  Canadian practice guidelines for surgical intra-abdominal infections.

Authors:  Anthony W Chow; Gerald A Evans; Avery B Nathens; Chad G Ball; Glen Hansen; Godfrey Km Harding; Andrew W Kirkpatrick; Karl Weiss; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

4.  Prognostic factors of the mortality of postoperative intraabdominal infections.

Authors:  N Torer; K Yorganci; D Elker; I Sayek
Journal:  Infection       Date:  2010-08       Impact factor: 3.553

5.  Adapted ERAS Pathway vs. Standard Care in Patients with Perforated Duodenal Ulcer-a Randomized Controlled Trial.

Authors:  Subair Mohsina; Dasarathan Shanmugam; Sathasivam Sureshkumar; Pankaj Kundra; T Mahalakshmy; Vikram Kate
Journal:  J Gastrointest Surg       Date:  2017-06-26       Impact factor: 3.452

Review 6.  Clinical predictors of ongoing infection in secondary peritonitis: systematic review.

Authors:  Bas Lamme; Cecilia W Mahler; Oddeke van Ruler; Dirk J Gouma; Johannes B Reitsma; Marja A Boermeester
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

7.  Prognostic scores and design of clinical studies.

Authors:  C Ohmann
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

8.  Survival after intestinal perforation: can it be predicted?

Authors:  Celestine S Tung; Charlotte C Sun; Matthew P Schlumbrecht; Larissa A Meyer; Diane C Bodurka
Journal:  Gynecol Oncol       Date:  2009-09-18       Impact factor: 5.482

9.  Evaluation of prognostic factors and scoring system in colonic perforation.

Authors:  Atsushi Horiuchi; Yuji Watanabe; Takashi Doi; Kouichi Sato; Syungo Yukumi; Motohira Yoshida; Yuji Yamamoto; Hiroki Sugishita; Kanji Kawachi
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

10.  Relaparotomies: Why is Mortality Higher?

Authors:  Ercan Gedik; Kazým Söylemez; Sadullah Girgin; Ersin Uysal; Ýbrahim Taçyýldýz
Journal:  Eur J Trauma Emerg Surg       Date:  2009-05-12       Impact factor: 3.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.